doi:10.19982/j.issn.1000-6621.20230382

Abstract

CLC Number:

R52
R564

Figures/Tables 2

References 16

[1]	Parish JM, Rosenow EC 3rd. , Mediastinal granuloma and mediastinal fibrosis. Semin Respir Crit Care Med, 2002, 23(2): 135-143. doi:10.1055/s-2002-25302. URL pmid: 16088606
[2]	Wang A, Su H, Duan Y, et al. Pulmonary hypertension caused by fibrosing mediastinitis. JACC Asia, 2022, 2(3): 218-234. doi:10.1016/j.jacasi.2021.11.016. URL pmid: 36338410
[3]	Garrana SH, Buckley JR, Rosado-de-Christenson ML, et al. Multimodality imaging of focal and diffuse fibrosing mediastinitis. Radiographics, 2019, 39(3): 651-667. doi:10.1148/rg.2019180143. URL pmid: 30951437
[4]	Lin J, Jimenez CA. Acute mediastinitis, mediastinal granuloma, and chronic fibrosing mediastinitis: A review. Semin Diagn Pathol, 2022, 39(2): 113-119. doi:10.1053/j.semdp.2021.06.008.
[5]	曹云山, 段一超, 苏红玲. 纤维纵隔炎致肺血管狭窄的诊治进展. 中华心血管病杂志, 2020, 48(10): 823-830. doi:10.3760/cma.j.cn112148-20200214-00081.
[6]	Fender EA, Widmer RJ, Knavel Koepsel EM, et al. Catheter based treatments for fibrosing mediastinitis. Catheter Cardiovasc Interv, 2019, 94(6): 878-885. doi:10.1002/ccd.28152.
[7]	廖纪萍, 胡艳, 邱建星, 等. 纵隔纤维化患者的临床特点及预后分析. 中华结核和呼吸杂志, 2017, 40(3): 199-204. doi:10.3760/cma.j.issn.1001-0939.2017.03.011.
[8]	张舒华, 林江涛, 王秀红, 等. 纤维素性纵隔炎的临床特征. 中国呼吸与危重监护杂志, 2021, 20(8): 564-569. doi:10.7507/1671-6205.202103026.
[9]	Hu Y, Qiu JX, Liao JP, et al. Clinical manifestations of fibrosing mediastinitis in Chinese patients. Chin Med J (Engl), 2016, 129(22): 2697-2702. doi:10.4103/0366-6999.193457.
[10]	Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J, 2019, 53(1): 1801913. doi:10.1183/13993003.01913-2018.
[11]	刘安琪, 邓美, 许文清, 等. 纤维素性纵隔炎的影像诊断. 中华放射学杂志, 2023, 57(3): 335-338. doi:10.3760/cma.j.cn112149-20220705-00577.
[12]	田火欢, 王凯歌, 谢玉芳, 等. 纤维素性纵隔炎的诊治进展. 中国呼吸与危重监护杂志, 2023, 22(7): 528-532. doi:10.7507/1671-6205.202304012.
[13]	曾谊, 高卫卫, 宫素岗, 等. 二例结核感染所致纵隔纤维化患者的临床诊治过程分析. 中国防痨杂志, 2020, 42(7): 747-751. doi:10.3969/j.issn.1000-6621.2020.07.019.
[14]	Peikert T, Colby TV, Midthun DE, et al. Fibrosing mediastinitis: clinical presentation, therapeutic outcomes, and adaptive immune response. Medicine (Baltimore), 2011, 90(6): 412-423. doi:10.1097/MD.0b013e318237c8e6.
[15]	Liu T, Gao L, Xie S, et al. Clinical and imaging spectrum of tuberculosis-associated fibrosing mediastinitis. Clin Respir J, 2018, 12(5): 1974-1980. doi:10.1111/crj.12766. URL pmid: 29356415
[16]	Albers EL, Pugh ME, Hill KD, et al. Percutaneous vascular stent implantation as treatment for central vascular obstruction due to fibrosing mediastinitis. Circulation, 2011, 123(13): 1391-1399. doi:10.1161/CIRCULATIONAHA.110.949180. URL pmid: 21422386

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 2

References 16

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407.
[3]	Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415.
[4]	Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424.
[5]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[6]	An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438.
[7]	Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443.
[8]	Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453.
[9]	Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459.
[10]	Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470.
[11]	Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476.
[12]	Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481.
[13]	Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497.
[14]	Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504.
[15]	Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512.